VirilizationE25.0

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Masculinization; Virilism; Virilization

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Development of male secondary sexual characteristics (male hair type = hirsutism, deep voice, clitoral hypertrophy) in women with obligatory increased androgen formation (e.g. in PCOS, SAHA syndrome, ovarian tumours, NNR tumours, exogenous androgen supply).

EtiopathogenesisThis section has been translated automatically.

Endogenous or exogenous androgen supply.

Clinical featuresThis section has been translated automatically.

Body and sexual hair in women corresponding to the male hair type, which is ovarian, adrenal or pituitary.

LaboratoryThis section has been translated automatically.

Differently pronounced hyperandrogenemia. There is not always a firm correlation between the concentration of circulating androgens and the clinical signs of androgenization. This means that, in addition to the bioavailability of androgens, the rate of utilisation in the target organs plays a role in clinical androgenic effects.

TherapyThis section has been translated automatically.

  • Causal therapy, if possible. Tumour search and, if necessary, remediation. Stop exogenous supply of hormone-containing substances. Otherwise antiandrogenic therapy with cyproterone acetate (e.g. Androcur) 2 mg/day in combination with ethinylestradiol 0.05 mg/day (e.g. Diane). Alternatively cyproterone acetate 2 mg/day in combination with ethinylestradiol 0.035 mg for 21 days, then 7 days rest, alternating over months to years. For more severe disorders Cyproterone acetate 25-200 mg/day for 10 days, 18 days break, in combination with ethinylestradiol (progynone) 0.04 mg/day, 21 days therapy, then 7 days break.
  • High-dose parenteral therapy (in case of failure of oral therapy): 300 mg cyproterone acetate (Androcur Depot) i.m. between the 3rd and 7th day of the cycle combined with 40 μg/day ethinylestradiol starting on the day of CPA injection, for 20 days.

LiteratureThis section has been translated automatically.

  1. Breckwoldt M (1992) Diagnosis and therapy of androgenisation symptoms in women. Diesbach publishing house
  2. Goodarzi MO et al (2003) Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormones. J Clin Endocrinol Metab 88: 73-77
  3. Mantovani G et al (2003) Isolated follicle-stimulating hormone (FSH) deficiency in a young man with normal virilization who did not have mutations in the FSHbeta gene. Fertil Sterile 79: 434-436

Authors

Last updated on: 29.10.2020